Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827495 | 0.91 | TK1 (0.46) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL14827489 | 0.87 | TK1 (0.44) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL14827484 | 0.84 | TK1 (0.48) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL10075974 | 0.83 | TK2 (0.46) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL19224114 | 0.81 | ALDH1A1 (0.57) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL14828628 | 0.81 | RNASE1 (0.62) | TK1TK2 | |
| SCHEMBL17885161 | 0.81 | RNASE1 (0.62) | TK1TK2 | |
| SCHEMBL22819195 | 0.81 | LMNA (0.52) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL9370470 | 0.81 | LMNA (0.52) | TK1ALBALDH1A1LMNAPOLB | |
| SCHEMBL5930585 | 0.81 | LMNA (0.52) | TK1ALBALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160186185-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9321799-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150159163-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8993738-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | TK1 525/4885ALB 4491/4885ALDH1A1 4054/4885 |
| US-20150159163-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | TK1 525/4885ALB 4491/4885ALDH1A1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.